vinblastine-N-oxide liposomal (CPD100Li) / Cascade Prodrug - LARVOL DELTA

Modulating the tumor microenvironment via hypoxia activated prodrug CPD100Li induced cell death synergistically enhances anti-CTLA-4 immunotherapy (SITC 2023) - "Feasibly, that CPD100Li induces changes in the tumor microenvironment that can convert ‘cold’ tumors into ‘hot’, promoting a strong anti-tumor response in combination with CTLA-4. This study demonstrates a novel and effective combination strategy for cancer immunotherapy, making it a potent candidate for cancer therapy in near future."

Biomarker • IO biomarker • Tumor microenvironment • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor • CD8 • PTPRC

Cascade Announces Poster Presentation at Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire) - "Cascade Prodrug Inc...today announced a poster presentation highlighting preclinical data for it's lead candidate CPD100Li at the SITC 2023 Annual Meeting, being held November 3-5 in San Diego, CA....Full text of the abstract will be available on the SITC website on Oct. 31 at 9am ET, and the poster will be made available on the Company’s website"

Preclinical